- Trade Name: Mulpleta (Shionogi)
- Indications: indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- Class: Thrombopoietin receptor (TPO) agonist
- Half-life: ~27 hours
- FDA Approval Date: 07/31/2018
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: no available data to inform the drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
